Microbiology Testing - Market Insights, Competitive Landscape, and Market Forecast - 2034

Microbiology Testing Market Summary

Overview:

• The global microbiology testing market was valued at USD 6.35 billion in 2025 and is projected to reach USD 13.79 billion by 2034.
• The market is expected to expand at a CAGR of 9.0% during the forecast period 2026-2034, supported by the rising prevalence of infectious diseases, the growing threat of antimicrobial resistance, continuous technological advancement in molecular and automated testing, and increasing concerns over food and pharmaceutical safety.
• By product, the instruments segment dominated the microbiology testing market with a 58% share in 2025.
• By test type, the bacterial segment dominated the microbiology testing market with a 54% share in 2025.
• By technology, the culture-based testing segment dominated the microbiology testing market with a 46% share in 2025.
• By application, the clinical diagnostics segment dominated the microbiology testing market with a 31% share in 2025.
• By end-user, the hospitals and diagnostic laboratories segment dominated the microbiology testing market with a 40% share in 2025.
• North America accounted for the largest share of the microbiology testing market at 42% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Microbiology testing is the laboratory analysis of samples to detect, identify, and quantify the microorganisms, including bacteria, viruses, fungi, and parasites, that cause infectious disease and contamination, supporting the diagnosis and treatment of infection, the surveillance of antimicrobial resistance, and the assurance of safety across food, pharmaceutical, and environmental applications. The market is organized by the product supplied, the type of test performed, the underlying technology, the application, and the setting of use. By product, it divides between the instruments that perform the testing and the reagents and consumables that they consume, together with the software and services that support them. By test type, it divides among the bacterial, viral, fungal, and parasitic testing that target the different classes of microorganisms. By technology, it spans the traditional culture-based methods that remain the foundation of the field, the molecular diagnostics that are its fastest-growing frontier, and the immunoassay and other methods that complement them. By application, it spans clinical diagnostics, food testing, pharmaceutical and biotechnology testing, and environmental testing, and by end-user it spans hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutes, and the food and beverage industry. The market is driven by the rising burden of infectious disease, the escalating threat of antimicrobial resistance, the migration toward rapid molecular and automated testing, and the stringent safety requirements of the food and pharmaceutical industries.

Microbiology Testing Market Key Growth Drivers

• The rising prevalence and incidence of infectious diseases and the recurring threat of epidemics and pandemics, which drive the demand for the accurate and timely detection of pathogens.
• The escalating global threat of antimicrobial resistance, which drives demand for rapid pathogen identification and antimicrobial susceptibility testing to guide appropriate therapy and stewardship.
• Continuous technological advancement, including molecular diagnostics, laboratory automation, mass-spectrometry identification, and artificial intelligence, which improve the speed, accuracy, and throughput of testing.
• Increasing concerns over food safety and stringent regulation, with the World Health Organization estimating that some 600 million people suffer foodborne illness each year, much of it from microbiological contamination.
• The rising demand of the pharmaceutical and biotechnology industries for microbial quality control, sterility testing, and environmental monitoring across manufacturing.
• Growing healthcare expenditure and the expansion of diagnostic laboratory infrastructure, particularly across the emerging economies of Asia-Pacific.
• The aging of the population and the growth of the immunocompromised population, both of which increase susceptibility to infection and the demand for microbiological testing.

Key Companies in Microbiology Testing Market

The leading participants in the microbiology testing market include the following:

• Thermo Fisher Scientific Inc.
• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation (Cepheid)
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Abbott Laboratories
• QIAGEN N.V.
• Bruker Corporation
• Bio-Rad Laboratories, Inc.

Factors Contributing to the Growth of the Microbiology Testing Market

Market Drivers

Rising Prevalence of Infectious Diseases

The foundational driver of the microbiology testing market is the rising prevalence and incidence of infectious diseases, because the detection and identification of the microorganisms that cause infection is the central purpose of microbiology testing, and the burden of infectious disease directly determines the demand for it. Infectious diseases, from the endemic bacterial, viral, fungal, and parasitic infections that affect populations worldwide to the sexually transmitted, respiratory, bloodstream, gastrointestinal, and urinary tract infections encountered daily in clinical practice, generate a very large and continuing demand for the testing that detects and identifies their causative organisms, and the recurring threat of epidemics and pandemics, underscored by recent global experience, reinforces the strategic importance of microbiological testing and surveillance. The accurate and timely detection of pathogens is essential to the diagnosis and treatment of infection, to the isolation and control of outbreaks, and to the surveillance that protects public health, making microbiology testing an indispensable component of the healthcare system. The rising burden is driven by the growth and aging of the population, the expansion of the immunocompromised population, the emergence and re-emergence of pathogens, and the increasing recognition and diagnosis of infection, and each of these forces expands the volume of testing. Because infectious disease is a large, continuing, and rising burden, and because microbiology testing is essential to managing it, this driver provides the most durable foundation for market growth.

Escalating Threat of Antimicrobial Resistance

The escalating global threat of antimicrobial resistance is a powerful and distinctive driver of the microbiology testing market, because the response to resistance depends upon the rapid and accurate identification of pathogens and the testing of their susceptibility to antimicrobials, which is a core function of microbiology testing. Antimicrobial resistance, in which bacteria, fungi, and other microorganisms evolve to withstand the drugs used to treat them, is among the most serious threats to global health, and the World Health Organization and public health authorities have identified it as a priority demanding urgent action. The clinical and public health response to resistance rests upon microbiology testing, since the appropriate treatment of a resistant infection requires the identification of the causative organism and the determination of which antimicrobials remain effective against it through antimicrobial susceptibility testing, and the stewardship programs that seek to preserve the effectiveness of antimicrobials depend upon the rapid, accurate diagnostic information that microbiology testing provides. The demand for rapid pathogen identification and susceptibility testing, which allows clinicians to move quickly from empirical to targeted therapy, is a particularly strong driver of the adoption of the advanced molecular and automated testing that delivers results faster than traditional culture. Because antimicrobial resistance is a large, rising, and urgent threat, and because microbiology testing is central to the response to it, this driver is a powerful and durable contributor to market growth.

Market Restraints

Despite a large and rising burden of infectious disease and rapid technological advances, the microbiology testing market faces several material constraints. The most significant is the high cost of the advanced instruments and automation, since the acquisition of molecular diagnostic systems, mass-spectrometry identification, and laboratory automation is substantial, with total laboratory automation systems requiring upfront outlays of several million dollars per site, a hurdle that smaller community hospitals, independent laboratories, and providers in emerging markets struggle to clear, and the recurring cost of reagents and consumables adds to the total cost of ownership. This cost restricts the adoption of the most advanced testing to larger and better-resourced laboratories and slows the diffusion of new technology. A second constraint is the shortage of skilled microbiologists and laboratory technicians, since microbiology testing, particularly the interpretation of culture and susceptibility results and the operation of advanced molecular and automated systems, requires specialized training, and the limited availability of qualified personnel and of the formal training programs that produce them constrains both the capacity and the quality of testing, particularly in emerging markets. A third constraint is the slow turnaround of the traditional culture-based methods that remain the foundation of the field, since culture requires days to yield results, delaying diagnosis and treatment; although rapid molecular methods address this limitation, they carry higher costs and do not fully replace culture, which regulators and clinicians continue to require for definitive susceptibility results. Additional constraints include the pressure of reimbursement and laboratory budgets, the complexity and cost of the molecular testing menu, the regulatory requirements governing diagnostic devices, and the uneven laboratory infrastructure across much of the world. Together these cost, workforce, turnaround, and infrastructure factors ensure that growth, while strong, proceeds against genuine constraint.

Microbiology Testing Market Segment Analysis

The global microbiology testing market by product (instruments, reagents and consumables, and software and services), by test type (bacterial, viral, fungal, and parasitic), by technology (culture-based testing, molecular diagnostics, immunoassay, and others), by application (clinical diagnostics, food testing, pharmaceutical and biotechnology, and environmental), by end-user (hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutes, and the food and beverage industry), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product

Dominant Subsegment: Instruments.

The instruments segment accounted for a 58% share of the microbiology testing market in 2025. The instruments segment dominates the product structure because the automated culture, identification, susceptibility, and molecular systems that perform microbiology testing represent substantial capital equipment, and their widespread adoption across clinical, food, pharmaceutical, and environmental laboratories anchors the market. The instruments span the automated blood culture systems, the identification and susceptibility systems, the mass-spectrometry identification platforms, the molecular and polymerase chain reaction systems, and the laboratory automation that together constitute the modern microbiology laboratory, and the value of these systems, together with the continuing transition toward automation and molecular testing, sustains the leading position of the segment. The reagents and consumables segment constitutes the second product category and the fastest-growing, comprising the culture media, test kits, panels, and other consumables that the instruments require, which generate recurring revenue tied to test volume and which grow as the installed base of instruments and the volume of testing expand, so that the reagents segment is anticipated to grow fastest over the forecast period as the razor-and-blade economics of the installed base assert themselves. The software and services segment completes the structure, comprising the laboratory information and analytics software and the service and support that the instruments require. The instruments segment is expected to retain its leading share throughout the forecast period, while reagents and consumables grow fastest.

By Test Type

Dominant Subsegment: Bacterial.

The bacterial segment accounted for a 54% share of the microbiology testing market in 2025. Bacterial testing dominates the test-type structure because bacterial infections are the most common and most clinically significant of the infections that microbiology testing addresses, and because the identification of bacteria and the testing of their susceptibility to antimicrobials constitute the core workload of the microbiology laboratory. Bacterial infections, from the bloodstream, respiratory, urinary, gastrointestinal, and wound infections encountered daily in clinical practice to the foodborne and environmental contamination monitored across industry, generate the largest volume of microbiology testing, and the central role of bacterial testing in the diagnosis and treatment of infection and in the response to antimicrobial resistance, which is predominantly a bacterial phenomenon, sustains the leading position of the segment. The identification of the causative bacterium and the determination of its antimicrobial susceptibility, which guides the selection of effective therapy, are the defining tasks of clinical microbiology, and the growth of antimicrobial resistance intensifies the demand for them. The viral segment constitutes a substantial and fast-growing category, expanded by the demand for the molecular testing of respiratory, gastrointestinal, and other viral infections and reinforced by the experience of recent pandemics, and the fungal and parasitic segments, while smaller, address the serious and opportunistic infections that particularly affect immunocompromised patients. The bacterial segment is expected to retain its leading share throughout the forecast period, while viral testing grows rapidly.

Microbiology Testing Market Region Analysis

Dominant Region: North America

North America accounted for a 42% share of the global microbiology testing market in 2025. The region is expected to account for the largest share of the global market, driven by the high prevalence and awareness of infectious disease and antimicrobial resistance, the strong adoption of advanced molecular and automated testing, well-developed reimbursement and healthcare infrastructure, stringent food and pharmaceutical safety regulation, and the presence and commercial strength of the leading diagnostics companies. The United States hosts a large and technologically advanced network of hospitals, reference laboratories, and diagnostic laboratories that perform a very high volume of microbiology testing and are early adopters of the advanced molecular, mass-spectrometry, and automation technologies that define the modern field, and the strong reimbursement environment and high healthcare expenditure support the investment these systems require. The region leads in the response to antimicrobial resistance, in the adoption of rapid syndromic and molecular testing, and in the stringent food and pharmaceutical safety regulation that mandates microbiological testing, and it is the principal market for the newest diagnostic technologies, which are frequently cleared and launched first in the United States. The strong presence of the leading diagnostics companies and the well-developed research and public health laboratory infrastructure reinforce the position of the region. The region is expected to retain its leading position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the microbiology testing market through 2034. The region is emerging as the principal growth engine of the market, propelled by very large populations, a high and rising burden of infectious disease, expanding healthcare access and diagnostic laboratory infrastructure, rising healthcare expenditure, and increasing food and pharmaceutical safety regulation across China, India, Japan, and Southeast Asia. The region combines the largest populations in the world with a high burden of the infectious diseases that microbiology testing addresses, and the expansion and modernization of diagnostic laboratory infrastructure, driven by rising incomes, expanding healthcare access, and growing public and private investment, is converting this burden into demand for testing. Governments and private providers are investing in the laboratories, instruments, and personnel required to perform microbiology testing, in the strengthening of public health and surveillance capacity following the experience of recent pandemics, and in the food and pharmaceutical safety testing that rising regulation and a growing manufacturing base require. China combines a very large population with a rapidly developing diagnostics industry and manufacturing base, India combines a very large population and infectious disease burden with a rapidly expanding diagnostic laboratory sector, and Japan combines an aged population with a sophisticated and advanced testing market. The coexistence of demand for both advanced and cost-effective testing creates opportunity for international and regional companies alike. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value and adoption, holding a 42% share in 2025. The region combines a high burden and awareness of infectious disease and antimicrobial resistance, strong adoption of advanced molecular and automated testing, well-developed reimbursement and infrastructure, stringent food and pharmaceutical safety regulation, and the commercial strength of the leading diagnostics companies. It leads in the response to antimicrobial resistance and in the adoption of rapid syndromic and molecular testing, and it is typically the first market for new diagnostic technologies. Near-term dynamics are shaped by the migration to rapid molecular and syndromic testing, laboratory automation, antimicrobial stewardship, and the response to emerging pathogens.

Europe

Europe is a large and sophisticated market, and the home region of several of the leading companies, including major in vitro diagnostics and life-science firms, and it combines well-developed healthcare systems, strong public health and surveillance infrastructure, and stringent food and pharmaceutical safety regulation with Germany, France, and the United Kingdom as principal markets. The region combines a substantial and aging population with generally supportive public healthcare and with a strong regulatory emphasis upon antimicrobial resistance, food safety, and pharmaceutical quality. The In Vitro Diagnostic Medical Devices Regulation shapes the pace of introduction of new diagnostic tests, and the region sustains a competitive and advanced market served by both global and regional participants.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large populations, a high and rising burden of infectious disease, expanding healthcare access and diagnostic laboratory infrastructure, rising healthcare expenditure, and increasing regulation. The modernization and expansion of laboratory infrastructure is converting the large infectious disease burden into demand for testing. China combines a very large population with a developing diagnostics industry, India combines a very large population and disease burden with a rapidly expanding laboratory sector, and Japan combines an aged population with an advanced testing market. Both international and regional companies are expanding across the advanced and cost-effective segments. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. The burden of infectious disease is high across all three, and the region carries a substantial and rising demand for microbiology testing. The Gulf states combine high healthcare investment with advanced laboratory infrastructure, and the larger Latin American markets, particularly Brazil, support established diagnostic laboratory sectors and growing adoption of advanced testing, together representing steady growth. Much of Africa carries a very high infectious disease burden but faces severe constraints in laboratory infrastructure, personnel, and funding, so testing capacity is concentrated in the larger urban, private, and public health laboratories, with substantial unmet need. Regional growth will be driven by the high disease burden, expanding healthcare access and laboratory infrastructure, strengthening public health capacity, and the availability of cost-appropriate testing.

Microbiology Testing Market Competitive Landscape

The global microbiology testing market is classified as Moderately Concentrated. The market is led by a group of large diversified diagnostics and life-science companies with broad instrument, reagent, and molecular portfolios, which hold significant combined share, complemented by specialized microbiology and molecular diagnostics firms. Competition centers upon the breadth and menu of the testing portfolio, the speed and accuracy of results, the degree of automation, the installed base and its recurring reagent revenue, integration with laboratory information systems, and increasingly upon rapid molecular and syndromic testing and the response to antimicrobial resistance. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a group of large diversified diagnostics and life-science companies holding significant combined share across the instrument, reagent, and molecular segments alongside specialized microbiology and molecular diagnostics firms, and with the installed base, menu breadth, regulatory capability, and scale of the leaders constituting a barrier to entry.
• Leading players: Thermo Fisher Scientific, bioMerieux, and Becton Dickinson lead the broad microbiology market through extensive instrument and reagent portfolios, with bioMerieux a microbiology specialist leader, Danaher through Cepheid strong in molecular and point-of-care testing, Roche, Abbott, and QIAGEN strong in molecular diagnostics, Bruker in mass-spectrometry identification, and Merck KGaA and Bio-Rad in defined segments.
• Geographic reach: The leading participants maintain global commercial, distribution, and service organizations, decisive because microbiology testing is a global market requiring local sales, service, and regulatory presence, while specialized firms reach broader geographies through distribution and regional manufacturers serve domestic and cost-sensitive markets, particularly across Asia-Pacific.
• Product portfolio strength: Competitive advantage rests upon offering a broad menu spanning culture, identification, susceptibility, and molecular testing, upon the automation that improves throughput and addresses personnel shortages, and upon the installed base that generates recurring reagent revenue, with the leaders competing on the breadth and speed of their testing menus and specialized firms on a superior technology such as syndromic molecular panels or mass-spectrometry identification.
• Pipeline strength: Development is concentrated in rapid molecular and syndromic panel testing, rapid antimicrobial susceptibility testing, mass-spectrometry identification, laboratory automation, point-of-care and near-patient testing, artificial-intelligence-enabled interpretation, and the expansion of test menus across clinical, food, and pharmaceutical applications.
• Strategic partnerships: Collaboration spans partnerships between diagnostics companies and hospitals, laboratories, and public health agencies, the integration of testing with laboratory information and health information systems, co-development of assays and panels, and partnerships that extend menus and geographic reach.
• M&A activity: Acquisition and consolidation have shaped the field, including the acquisition of molecular diagnostics, rapid testing, and automation capability by the diversified leaders, exemplified by the building of molecular and point-of-care portfolios, and the acquisition of specialized microbiology and technology firms to expand menus and capabilities.
• Innovation focus: Innovation is shifting toward rapid molecular and syndromic testing that delivers results in hours, rapid antimicrobial susceptibility testing that accelerates targeted therapy, laboratory automation that addresses throughput and personnel constraints, point-of-care testing that extends microbiology beyond the central laboratory, and artificial intelligence in interpretation and workflow.
• Regulatory standing: Regulatory clearance and approval for diagnostic devices in the major jurisdictions, including United States Food and Drug Administration clearance and CE marking under the In Vitro Diagnostic Medical Devices Regulation, is a decisive credential, and the stringent regulation of diagnostic, food safety, and pharmaceutical testing both raises the barrier to entry and rewards the scale and regulatory capability of the leading companies.

Microbiology Testing Market Recent Developmental Activities

In September 2025, bioMerieux received United States Food and Drug Administration clearance for anterior nasal swab testing on its BIOFIRE Spotfire platform, extending the Spotfire respiratory and sore-throat panel, a rapid multiplex polymerase chain reaction test that detects common viral and bacterial causes within fifteen minutes, to a more comfortable sample-collection method. Strategic significance: the extension of rapid near-patient syndromic testing to a more comfortable sample type reinforced the migration of microbiology testing toward fast, accessible, molecular point-of-care formats and the competition to bring syndromic testing closer to the patient.

Microbiology Testing Market Segmentation

Microbiology Testing Market Assessment by Product

• Instruments
• Reagents and Consumables
• Software and Services

Microbiology Testing Market Assessment by Test Type

• Bacterial
• Viral
• Fungal
• Parasitic

Microbiology Testing Market Assessment by Technology

• Culture-Based Testing
• Molecular Diagnostics
• Immunoassay
• Others

Microbiology Testing Market Assessment by Application

• Clinical Diagnostics
• Food Testing
• Pharmaceutical and Biotechnology
• Environmental

Microbiology Testing Market Assessment by End-User

• Hospitals and Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Food and Beverage Industry

Microbiology Testing Market Assessment by Geography

• North America
• United States Microbiology Testing Market Size in USD million (2023-2034)
• Canada Microbiology Testing Market Size in USD million (2023-2034)
• Mexico Microbiology Testing Market Size in USD million (2023-2034)
• Europe
• France Microbiology Testing Market Size in USD million (2023-2034)
• Germany Microbiology Testing Market Size in USD million (2023-2034)
• United Kingdom Microbiology Testing Market Size in USD million (2023-2034)
• Italy Microbiology Testing Market Size in USD million (2023-2034)
• Spain Microbiology Testing Market Size in USD million (2023-2034)
• Rest of Europe Microbiology Testing Market Size in USD million (2023-2034)
• Asia-Pacific
• China Microbiology Testing Market Size in USD million (2023-2034)
• Japan Microbiology Testing Market Size in USD million (2023-2034)
• India Microbiology Testing Market Size in USD million (2023-2034)
• Australia Microbiology Testing Market Size in USD million (2023-2034)
• South Korea Microbiology Testing Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Microbiology Testing Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Microbiology Testing Market Size in USD million (2023-2034)
• Africa Microbiology Testing Market Size in USD million (2023-2034)
• South America Microbiology Testing Market Size in USD million (2023-2034)

Key Takeaways from the Microbiology Testing Market Report Study

• Market size analysis for the current microbiology testing market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global microbiology testing market.
• Various opportunities available for competitors in the microbiology testing market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current microbiology testing market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for microbiology testing market growth in the future?

Target audience who can benefit from this microbiology testing market report study

• Microbiology Testing product providers
• Research organizations and consulting companies
• Microbiology testing-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in microbiology testing
• Various end-users who want to know more about the microbiology testing market and the latest developments in the microbiology testing market.

Frequently Asked Questions:

Q1. At what rate is the microbiology testing market expected to grow?

The global microbiology testing market is projected to grow at a compound annual growth rate of 9.0% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the microbiology testing market?

On a DelveInsight-modeled basis, the global microbiology testing market was valued at USD 6.35 billion in 2025 and is projected to reach USD 13.79 billion by 2034.

Q3. Which region dominates the microbiology testing market?

North America dominated the microbiology testing market with a 42% share in 2025 on a modeled basis, driven by the high burden and awareness of infectious disease and antimicrobial resistance, strong adoption of advanced molecular and automated testing, well-developed reimbursement and infrastructure, stringent food and pharmaceutical safety regulation, and the presence of the leading diagnostics companies. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by very large populations, a high and rising burden of infectious disease, expanding healthcare access and diagnostic laboratory infrastructure, and increasing regulation across China, India, Japan, and Southeast Asia.

Q4. What are the key factors driving growth in the microbiology testing market?

The principal drivers are the rising prevalence of infectious diseases and the recurring threat of epidemics; the escalating threat of antimicrobial resistance, which drives demand for rapid pathogen identification and susceptibility testing; continuous technological advancement in molecular diagnostics, automation, and mass spectrometry; increasing food safety concerns and regulation, with the World Health Organization estimating some 600 million foodborne illnesses each year; the pharmaceutical and biotechnology demand for microbial quality control; growing healthcare expenditure and laboratory infrastructure; and the aging and immunocompromised populations.

Q5. Who are the major players in the microbiology testing market?

The market is moderately concentrated and led by Thermo Fisher Scientific Inc., bioMerieux SA, and Becton, Dickinson and Company, alongside Danaher Corporation through Cepheid in molecular and point-of-care testing, F. Hoffmann-La Roche Ltd., Merck KGaA, Abbott Laboratories, QIAGEN N.V., Bruker Corporation, and Bio-Rad Laboratories, Inc. Additional participants include Hologic, Inc., Agilent Technologies, Inc., NEOGEN Corporation, Shimadzu Corporation, DiaSorin S.p.A. (Luminex), and Charles River Laboratories.